Blood Biomarker May Help Identify Those at Increased Risk for RCC

Concentrations of KIM-1 in the blood may predict for renal cell carcinoma up to 5 years prior to diagnosis.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

AbstractPurposeTo compare the outcomes of percutaneous ablation (PA) versus nephrectomy (NE) for small renal masses (SRMs) in patients with T1 renal cell carcinoma and evaluate the role of  pre-procedural biopsy in the treatment of SRM.Materials and MethodsRetrospective cohort analysis of patients subjected to PA or NE for SRM (
Source: CardioVascular and Interventional Radiology - Category: Radiology Source Type: research
Publication date: Available online 14 November 2018Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Maria V. Chatziathanasiadou, Evgenios K. Stylos, Efstathia Giannopoulou, Maria-Helen Spyridaki, Evangellos Briasoulis, Haralabos P. Kalofonos, Tim Crook, Nelofer Syed, Gregory B. Sivolapenko, Andreas G. TzakosAbstractSunitinib is a multi-targeted tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor and is currently being investigated against other forms of malignant tumors. Recently a great interest has been emerged for the appli...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
ConclusionThe findings from the study suggested that there were pathological differences in multifocal renal tumors, and that papillary carcinoma may be more common than clear cell carcinoma. The recurrence rate and survival rate of multifocal RCC were similar to monofocal tumors. Tumor recurrence may be related to satellite tumor nodules, which can only be detected once surgery is performed.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 12 November 2018Source: European UrologyAuthor(s): Suzanne B. Merrill
Source: European Urology - Category: Urology & Nephrology Source Type: research
In patients with previously untreated advanced renal cell carcinoma (RCC) whose tumors were positive for the PD-L1 checkpoint, a combination of the checkpoint inhibitor avelumab and the tyrosine kinase inhibitor (TKI) axitinib increased the median PFS from 8.4 months to 13.8 months when compared with the TKI sunitinib (HR 0.69; P=0.0001).11/14/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and survival, and additionally plays an important role in immune regulation. Since mTOR inhibitors were shown to benefit immunosuppressive regulatory T-cell (Treg) expansion, this might suppress antitumor immune responses. Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs.11/14/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
CIP2A is a well-known oncoprotein whose expression is elevated in multiple human solid tumor types. However, its role in renal cell carcinoma (RCC) development is poorly understood.11/14/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy.11/14/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife.11/14/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
Metastasis is the primary cause of death in renal cell carcinoma (RCC). Loss of cell-to-cell adhesion, including tight junctions (TJs) is the initial step in the process of metastasis. Claudin-7 (CLDN7) is a m...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Legislation | Renal Cell Carcinoma